Rezolute Inc. Seeks $90 Million Boost Amid Promising Clinical Advances in Rare Disease Treatment.
Rezolute Inc. has navigated a financial rollercoaster with a $90 million stock offering, while making promising progress in its clinical trials for its lead asset Ersodetug, a treatment for hypoglycemia caused by hyperinsulinism.
3 minutes to read